For research use only. Not for therapeutic Use.
GR 103691 is a potent, selective dopamine D3 receptor antagonist with a Ki value of 0.4 nM. GR 103691 shows more than 100-fold selectivity for human dopamine human (h)D3 over hD4 and hD1 sites[1].
GR 103691 shows marked affinity for serotonin1A (5-HT1A) receptors (Ki of 5.8 nM) and α-1 adrenoceptors (Ki of 12.6 nM)[1].
Catalog Number | M033653 |
CAS Number | 162408-66-4 |
Synonyms | 4-(4-acetylphenyl)-N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]benzamide |
Molecular Formula | C30H35N3O3 |
Purity | ≥95% |
InChI | InChI=1S/C30H35N3O3/c1-23(34)24-9-11-25(12-10-24)26-13-15-27(16-14-26)30(35)31-17-5-6-18-32-19-21-33(22-20-32)28-7-3-4-8-29(28)36-2/h3-4,7-16H,5-6,17-22H2,1-2H3,(H,31,35) |
InChIKey | JARNORYOPMINDY-UHFFFAOYSA-N |
SMILES | CC(=O)C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)NCCCCN3CCN(CC3)C4=CC=CC=C4OC |
Reference | [1]. Audinot V, et al. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. J Pharmacol Exp Ther. 1998 Oct;287(1):187-97. |